Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. (scientific article)

Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study

Q36538133

The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis

Q37306246

Non-invasive fetal RHD genotyping tests: a systematic review of the quality of reporting of diagnostic accuracy in published studies

Q37350274

Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects

Q37351817

Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service

Q40626763

Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a meta-analysis.

Q53597278

Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis.

Q54574187

Fetal rhd genotyping from maternal plasma in a population with a highly diverse ethnic background.

Q54581839

Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma.

Q54646324

Prenatal genotyping of RHD and SRY using maternal blood.

Q54741354

Presence of fetal DNA in maternal plasma and serum

Q57075132

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation

Q57523616

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A

Q57917851

P433

issue

P921

main subject

genotyping

Q912147

P304

page(s)

301-306

P577

publication date

2011-01-08

P1433

published in

Fetal Diagnosis and Therapy

Q15765765

P1476

title

Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation.

P478

volume

Reverse relations

cites work (P2860)

Q43787267	Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population.
Q50489938	Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
Q43448023	Costs and benefits of non-invasive fetal RhD determination
Q43599210	Evaluation of sample stability and automated DNA extraction for fetal sex determination using cell-free fetal DNA in maternal plasma
Q34472967	Haemolytic disease of the fetus and newborn
Q64243238	High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis
Q40901636	How to evaluate PCR assays for the detection of low-level DNA.
Q35674630	Implementing non-invasive RHD genotyping on cell-free foetal DNA from maternal plasma: the Pavia experience
Q38178923	Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care
Q35507579	Non-Invasive Prenatal RHD Genotyping Using Cell-Free Fetal DNA from Maternal Plasma: An Italian Experience
Q90396106	Non-invasive prenatal rhesus D genotyping using cell-free foetal DNA
Q87466211	Noninvasive fetal RhD genotyping
Q35034936	Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD
Q54088983	Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.
Q43605070	Should cell-free DNA testing be used to target antenatal rhesus immune globulin administration?
Q89599771	Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review